Future research directions in idiopathic pulmonary fibrosis: Summary of a National Heart, Lung, and Blood Institute Working Group

American Journal of Respiratory and Critical Care Medicine

Volumn 166, Issue 2, 2002, Pages 236-246

  Crystal, Ronald G ^{a,b,c,d,e,f,g,h,i,j,k,l,m,n,o}   Bitterman, Peter B ^{a,b,c,d,e,f,g,h,i,j,k,l,m,n,o}   Mossman, Brooke ^{a,b,c,d,e,f,g,h,i,j,k,l,m,n,o}   Schwarz, Marvin I ^{a,b,c,d,e,f,g,h,i,j,k,l,m,n,o}   Sheppard, Dean ^{a,b,c,d,e,f,g,h,i,j,k,l,m,n,o}   Almasy, Laura ^{a,b,c,d,e,f,g,h,i,j,k,l,m,n,o}   Chapman, Harold A ^{a,b,c,d,e,f,g,h,i,j,k,l,m,n,o}   Friedman, Scott L ^{a,b,c,d,e,f,g,h,i,j,k,l,m,n,o}   King Jr , Talmadge E ^{a,b,c,d,e,f,g,h,i,j,k,l,m,n,o}   Leinwand, Leslie A ^{a,b,c,d,e,f,g,h,i,j,k,l,m,n,o}   Liotta, Lance ^{a,b,c,d,e,f,g,h,i,j,k,l,m,n,o}   Martin, George R ^{a,b,c,d,e,f,g,h,i,j,k,l,m,n,o}   Schwartz, David A ^{a,b,c,d,e,f,g,h,i,j,k,l,m,n,o}   Schultz, Gregory S ^{a,b,c,d,e,f,g,h,i,j,k,l,m,n,o}   Wagner, Carston R ^{a,b,c,d,e,f,g,h,i,j,k,l,m,n,o}   Musson, Robert A ^{a,b,c,d,e,f,g,h,i,j,k,l,m,n,o,p}  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^c UNIVERSITY OF VERMONT   (United States)

^d UNIVERSITY OF COLORADO   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f SOUTHWEST FOUNDATION FOR BIOMEDICAL RESEARCH   (United States)

^g UNIVERSITY OF CALIFORNIA   (United States)

^h MOUNT SINAI SCHOOL OF MEDICINE   (United States)

ⁱ UNIVERSITY OF COLORADO   (United States)

^j NATIONAL CANCER INSTITUTE   (United States)

^k FIBROGEN INC   (United States)

^l DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^m UNIVERSITY OF FLORIDA   (United States)

ⁿ UNIVERSITY OF MINNESOTA   (United States)

^o NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

^p MSC 7922 ^*  (United States)

more..

Author keywords

Lung diseases, interstitial; National Institutes of Health (United States); Pulmonary fibrosis

Indexed keywords

ALPHA INTERFERON; ANTIVIRUS AGENT; ARACHIDONIC ACID DERIVATIVE; CONNECTIVE TISSUE GROWTH FACTOR; DECORIN; ENDOTHELIN RECEPTOR ANTAGONIST; GAMMA INTERFERON; NEUTRALIZING ANTIBODY; TRANSFORMING GROWTH FACTOR BETA;

APOPTOSIS; CELL PROLIFERATION; CONFERENCE PAPER; DISEASE COURSE; DRUG DELIVERY SYSTEM; ENZYME ACTIVATION; EXTRACELLULAR MATRIX; FIBROGENESIS; HUMAN; IDIOPATHIC DISEASE; IMMUNE SYSTEM; INHIBITION KINETICS; LIVER FIBROSIS; LUNG FIBROSIS; MASS SPECTROMETRY; MEDICAL RESEARCH; MOLECULAR DYNAMICS; MYOFIBROBLAST; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; REGULATORY MECHANISM;

HUMANS; PULMONARY FIBROSIS; RESEARCH;

EID: 0037099443     PISSN: 1073449X     EISSN: None     Source Type: Journal    
DOI: 10.1164/rccm.2201069     Document Type: Conference Paper

References (85)

1. Idiopathic pulmonary fibrosis: Diagnosis and treatment. International consensus statement
2. The epidemiology of interstitial lung diseases
3. Accuracy of mortality data for interstitial lung diseases in New Mexico, USA
4. Prognostic significance of histopathologic subsets in idiopathic pulmonary fibrosis
5. The prognostic significance of the histologic pattern of interstitial pneumonia in patients presenting with the clinical entity of cryptogenic fibrosing alveolitis
6. Idiopathic pulmonary fibrosis: Impact of oxygen and colchicine, prednisone, or no therapy on survival
7. The prognostic significance of the histologic pattern of interstitial pneumonia in patients presenting with the clinical entity of cryptogenic fibrosing alveolitis
8. Idiopathic pulmonary fibrosis: Clinical relevance of pathologic classification
9. American Thoracic Society/European Respiratory Society international multidisciplinary consensus classification of idiopathic interstitial pneumonias: General principles and recommendations
10. An immunohistochemical study of architectural remodeling and connective tissue synthesis in pulmonary fibrosis
11. Patterns of lung repair: A morphologist's view
12. The roles of the myofibroblast in idiopathic pulmonary fibrosis: Ultrastructural and immunohistochemical features of sites of active extracellular matrix synthesis
13. Idiopathic pulmonary fibrosis: Prevailing and evolving hypotheses about its pathogenesis and implications for therapy
14. Fibroblasts isolated after fibrotic lung injury induce apoptosis of alveolar epithelial cells in vitro
15. Alveolar epithelial cell death adjacent to underlying myofibroblasts in advanced fibrotic human lung
16. Lung myofibroblasts
17. Proceedings of the international congress on bronchiolitis obliterans organizing pneumonia
18. Intra-alveolar fibrosis of idiopathic bronchiolitis obliterans-organizing pneumonia: Cell-matrix patterns
19. Localization of matrix metalloproteinases-1, -2, and -9 and tissue inhibitor of metalloproteinase-2 in interstitial lung diseases
20. Apoptotic activity is increased in the newly formed fibromyxoid connective tissue in bronchiolitis obliterans organizing pneumonia
21. TIMP-1, -2, -3 and -4 in idiopathic pulmonary fibrosis: A prevailing nondegradative lung microenvironment?
22. Immunohistochemical study of metalloproteinases and their tissue inhibitors in the lungs of patients with diffuse alveolar damage and idiopathic pulmonary fibrosis
23. New aspects of hepatic fibrosis
24. Myofibroblasts. I. Paracrine cells important in health and disease
25. Sarcomeric gene expression and contractility in myofibroblasts
26. Regulation of alpha smooth muscle actin gene expression in myofibroblast differentiation from rat lung fibroblasts
27. Molecular regulation of hepatic fibrosis: An integrated cellular response to tissue injury
28. Effect of antibody to transforming growth factor beta on bleomycin induced accumulation of lung collagen in mice
29. Reduction of bleomycin induced lung fibrosis by transforming growth factor beta soluble receptor in hamsters
30. Latent transforming growth factor-beta: Structural features and mechanisms of activation
31. Thrombospondin causes activation of latent transforming growth factor-beta secreted by endothelial cells by a novel mechanism
32. Thrombospondin-1 is a major activator of TGF-beta1 in vivo
33. Plasmin regulates the activation of cell-associated latent TGF-beta 1 secreted by rat alveolar macrophages after in vivo bleomycin injury
34. The integrin αvβ6 binds and activates latent TGFβ1: A mechanism for regulating pulmonary inflammation and fibrosis
35. Differential proliferation of fibroblasts cultured from normal and fibrotic human lung
36. Fibroblasts from idiopathic pulmonary fibrosis and normal lungs differ in growth rate, apoptosis and tissue inhibitor of metalloproteinases expression
37. Apoptosis and expression of Fas/Fas ligand mRNA in bleomycin-induced pulmonary fibrosis in mice
38. Induction of apoptosis and pulmonary fibrosis in mice in response to ligation of Fas antigen
39. Laser-based microscopic approaches: Application to cell signaling in environmental lung disease
40. Bleomycin-induced pulmonary fibrosis in transgenic mice that either lack or overexpress the murine plasminogen activator inhibitor-1 gene
41. Abnormalities in pathways of alveolar fibrin turnover among patients with interstitial lung disease
42. Recombinant human protein C worldwide evaluation in severe sepsis (PROWESS) study group: Efficacy and safety of recombinant human activated protein C for severe sepsis
43. The metalloproteinase matrilysin proteolytically generates active soluble F ligand and potentiates epithelial cell apoptosis
44. Presenilin 2 deficiency causes a mild pulmonary phenotype and no changes in amyloid precursor protein processing but enhances the embryonic lethal phenotype of presenilin 1 deficiency
45. Comparative tissue repair
46. Effect of transforming growth factor beta on post operative adhesions formation and intact peritoneum
47. Human anti-transforming growth factor-beta2 antibody: A new glaucoma anti-scarring agent
48. Connective tissue growth factor mediates transforming growth factor beta-induced collagen synthesis: Down-regulation by cAMP
49. Linkage strategies for mapping genes for complex traits in man
50. Gene mapping in the 20th and 21st centuries: Statistical methods, data analysis, and experimental design
51. Frequency in relatives of an all-or-none trait
52. Linkage strategies for genetically complex traits. II. The power of affected relative pairs
53. Quantitative trait locus mapping using human pedigrees
54. Inherited forms of interstitial lung disease
55. Genetic predisposition of interstitial lung disease
56. Familial idiopathic pulmonary fibrosis: Evidence of lung inflammation in unaffected family members
57. Non-specific interstitial pneumonia as pulmonary involvement of systemic sclerosis
58. Cyclophosphamide is associated with pulmonary function and survival benefit in patients with scleroderma and alveolitis
59. Functional genomics and expression profiling: Be there or be square
60. Global analysis of gene expression in pulmonary fibrosis reveals distinct programs regulating lung inflammation and remodeling
61. TGF-β is a critical mediator of acute lung injury
62. Laser capture microdissection
63. Cell sampling: Laser capture microdissection: Molecular analysis of tissue
64. Idiopathic pulmonary fibrosis: Diagnosis and management: International consensus statement
65. Hepatic fibrosis: Pathogenesis and principles of therapy
66. Interferon-alpha 2b therapy reduces liver fibrosis in chronic non-A, non-B hepatitis: A quantitative histological evaluation
67. A preliminary study of long-term treatment with interferon gamma-1b and low-dose prednisolone in patients with idiopathic pulmonary fibrosis
68. Transforming growth factor beta 1 is present at sites of extracellular matrix gene expression in human pulmonary fibrosis
69. Transforming growth factor-beta gene transfer to the lung induces myofibroblast presence and pulmonary fibrosis
70. Adenovector-mediated gene transfer of active transforming growth factor-beta 1 induces prolonged severe fibrosis in rat lung
71. Adenovirus-mediated decorin gene transfer prevents TGF-β-induced inhibition of lung morphogenesis
72. CTGF mRNA is upregulated in bleomycin-induced lung fibrosis
73. Autocrine overexpression of CTGF maintains fibrosis
74. A cytokine reborn? Endothelin-1 in pulmonary inflammation and fibrosis
75. Inhibition of prolyl-4-hydroxylase in vitro and in vivo by members of a novel series of phenanthrolinones
76. Tumor necrosis factor interacts with interleukin-1 and interferons to inhibit fibroblast proliferation via prostaglandin-dependent and independent mechanisms
77. Modulation of alveolar macrophage-driven fibroblast proliferation by alternative macrophage mediators
78. Mononuclear cell modulation of connective tissue function: Suppression of fibroblast growth by stimulation of endogenous prostaglandin production
79. The effect and interaction of bradykinin and prostaglandins on protein and collagen production by lung fibroblasts
80. 2 and to express cyclooxygenase-2
81. Constitutive activation of 5-lipoxygenase in the lungs of patients with idiopathic pulmonary fibrosis
82. Protection from pulmonary fibrosis in leukotriene-deficient mice
83. The 5-lipoxygenase pathway: A new therapeutic target for the treatment of pulmonary fibrosis
84. Overexpression of alveolar macrophage gelatinase B (MMP-9) in patients with idiopathic pulmonary fibrosis: Effects of steroid and immunosuppressive treatment